-
1.发明公开METHODS, COMPOSITIONS, USES, AND KITS USEFUL FOR VITAMIN D DEFICIENCY AND RELATED DISORDERS 有权方法，组合物，用途及试剂盒健身维生素D缺乏性及相关疾病
公开(公告)号：EP2281058A1
公开(公告)日：2011-02-09
申请号：EP09729007.6
申请日：2009-04-02
CPC分类号： G01N33/82 , A61K31/00 , A61K31/59 , A61K31/592 , A61K31/593 , A61K45/06 , C12Q1/6876 , C12Q1/6883 , C12Q2600/106 , C12Q2600/158 , G01N33/6893 , G01N2333/50 , G01N2333/90251 , G01N2800/04 , G01N2800/046 , G01N2800/347
摘要： Methods for diagnosing, treating, and preventing catabolism-related vitamin D deficiency and related disorders; related compositions, apparatus and kits, are disclosed. A method involves measuring CYP24 expression and/or activity, or a proxy thereof such as FGF23 level, in a patient and correlating abnormally elevated CYP24 expression and/or activity with catabolism- related vitamin D deficiency or with susceptibility for catabolism-related vitamin D deficiency. In response to abnormally elevated CYP24 expression and/or activity, the method further includes administering a CYP24 inhibitor to the vitamin D deficient or at-risk patient, and preferably avoiding activation of the vitamin D binding receptor, such as by avoiding administration of active vitamin D compounds to such patients. Optionally, a vitamin D prohormone or prohormone can be administered.
-
公开(公告)号：EP2037936B1
公开(公告)日：2014-06-11
申请号：EP07840277.3
申请日：2007-06-21
发明人： BISHOP, Charles, W. , CRAWFORD, Keith, H. , MESSNER, Eric, J. , PETKOVICH, P. Martin , HELVIG, Christian, F.
CPC分类号： A61K31/593 , A61K9/48 , A61K31/59 , A61K31/592
摘要： A method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 , and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D 3 for 25-hydroxyvitamin D repletion and/or maintenance.
-
公开(公告)号：EP2037936A2
公开(公告)日：2009-03-25
申请号：EP07840277.3
申请日：2007-06-21
发明人： BISHOP, Charles, W. , CRAWFORD, Keith, H. , MESSNER, Eric, J. , PETKOVICH, Martin, P. , HELVIG, Christian, F.
CPC分类号： A61K31/593 , A61K9/48 , A61K31/59 , A61K31/592
摘要： A method of treating elevated blood levels of iPTH by increasing or maintaining blood concentrations of both 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D in a patient by administering, as necessary, both Vitamin D repletion and Vitamin D hormone replacement therapies, is disclosed. The blood concentrations of 25-hydroxyvitamin D are increased to and maintained at or above 30 ng/mL, and blood concentrations of 1,25-dihydroxyvitamin D are increased to or maintained within a patient's normal historical physiological range for 1,25-dihydroxyvitamin D without causing substantially increased risk of hypercalcemia, hyperphosphatemia or over suppression of plasma iPTH in the patient. The blood levels of 25-hydroxyvitamin D are maintained at or above 30 ng/mL between doses of Vitamin D repletion therapies, and the blood levels of 1,25-dihydroxyvitamin D are maintained in the patient's normal historical physiological range between doses of Vitamin D hormone replacement therapies. In one aspect, the disclosure includes methods wherein the blood concentration of 25-hydroxyvitamin D during treatment comprises predominantly 25-hydroxyvitamin D 3 , and/or wherein the method includes administering predominantly or solely 25-hydroxyvitamin D 3 for 25-hydroxyvitamin D repletion and/or maintenance.
-
公开(公告)号：EP2148684B1
公开(公告)日：2013-01-16
申请号：EP08837933.4
申请日：2008-04-25
申请人： Cytochroma Inc.
IPC分类号： A61K31/592 , A61K31/593 , A61P43/00
CPC分类号： A61K31/592 , A61K31/593
-
公开(公告)号：EP2389183A1
公开(公告)日：2011-11-30
申请号：EP10733188.6
申请日：2010-01-26
申请人： Cytochroma Inc.
IPC分类号： A61K31/66 , A61K31/661 , A61K31/662 , A61K31/675 , A61P3/12
CPC分类号： A61K31/66 , A61K31/662 , A61K31/663 , A61K31/675 , A61K45/06 , A61K2300/00
摘要： This invention relates to methods and small molecules having a phosphate group that can be used to inhibit phosphate transport and to treat or prevent diseases that are related to disorders in the maintenance of normal serum phosphate levels.
-
公开(公告)号：EP2148684A2
公开(公告)日：2010-02-03
申请号：EP08837933.4
申请日：2008-04-25
申请人： Cytochroma Inc.
IPC分类号： A61K31/592 , A61K31/593 , A61P43/00
CPC分类号： A61K31/592 , A61K31/593
摘要： The invention relates to methods and compositions for reducing toxicity associated with administration of vitamin D3, its 25-hydroxylated and 1-hydroxylated forms, and analogs thereof.
-
7.发明公开
公开(公告)号：EP2427484A1
公开(公告)日：2012-03-14
申请号：EP10740698.5
申请日：2010-05-03
申请人： Cytochroma Inc.
IPC分类号： C07K14/705 , G01N33/82
CPC分类号： C07K14/705 , C07K14/70567 , C07K2319/60 , G01N33/542 , G01N33/82 , G01N2333/70567 , G01N2800/347
摘要： Methods and compositions for measuring the amount of vitamin D derivatives are disclosed. Fluorescence Resonance Energy Transfer (FRET) in combination with a modified ligand-binding domain of the vitamin D receptor (LBD-VDR) to measure vitamin D derivatives are also disclosed.
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.011 秒)
